ATRS has been the subject of several other reports. Piper Sandler reiterated an overweight rating and set a $5.00 target price on shares of Antares Pharma in a research note on Sunday, June 21st. HC Wainwright reduced their target price on Antares Pharma from $5.00 to $4.50 and set a buy rating for the company in a research note on Wednesday, May 6th. Zacks Investment Research upgraded Antares Pharma from a sell rating to a hold rating in a research note on Tuesday, July 7th. Finally, LADENBURG THALM/SH SH reiterated a buy rating and set a $7.00 target price on shares of Antares Pharma in a research note on Sunday, June 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $5.63.
NASDAQ:ATRS opened at $2.61 on Wednesday. The firm has a market capitalization of $432.11 million, a price-to-earnings ratio of 130.57 and a beta of 1.36. Antares Pharma has a twelve month low of $1.60 and a twelve month high of $5.13. The stock’s 50 day moving average price is $2.75 and its two-hundred day moving average price is $3.00. The company has a quick ratio of 2.55, a current ratio of 3.01 and a debt-to-equity ratio of 0.85.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter. The company had revenue of $33.08 million for the quarter, compared to analyst estimates of $30.50 million. Antares Pharma had a return on equity of 2.38% and a net margin of 0.86%. As a group, analysts anticipate that Antares Pharma will post 0.02 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank boosted its stake in Antares Pharma by 1.4% in the 1st quarter. Swiss National Bank now owns 300,700 shares of the specialty pharmaceutical company’s stock valued at $710,000 after purchasing an additional 4,200 shares during the period. Aperio Group LLC boosted its stake in Antares Pharma by 28.5% in the 1st quarter. Aperio Group LLC now owns 25,433 shares of the specialty pharmaceutical company’s stock valued at $60,000 after purchasing an additional 5,646 shares during the period. Victory Capital Management Inc. boosted its stake in Antares Pharma by 28.6% in the 4th quarter. Victory Capital Management Inc. now owns 33,510 shares of the specialty pharmaceutical company’s stock valued at $157,000 after purchasing an additional 7,449 shares during the period. Envestnet Asset Management Inc. boosted its stake in Antares Pharma by 18.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 62,167 shares of the specialty pharmaceutical company’s stock valued at $292,000 after purchasing an additional 9,689 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Antares Pharma by 4.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 224,472 shares of the specialty pharmaceutical company’s stock valued at $617,000 after purchasing an additional 9,895 shares during the period. Institutional investors and hedge funds own 40.16% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: Trading Ex-Dividend Strategy
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.